The missing protein in Duchenne muscular dystrophy (DMD) is dystrophin. This large, rod-shaped protein normally acts as a shock absorber inside muscle fibers, connecting the internal skeleton of each muscle cell to its outer membrane. Without it, muscles break down progressively every time they contract, leading to the severe and progressive weakness that defines DMD.
What Dystrophin Does in Healthy Muscle
Dystrophin sits just beneath the surface membrane of every muscle fiber. It works as a structural bridge: one end anchors to the cell’s internal scaffolding (a network of actin filaments), and the other end connects to a cluster of proteins embedded in the cell membrane called the dystrophin-glycoprotein complex. That complex, in turn, links to the tough matrix of connective tissue surrounding each fiber.
The result is a continuous chain of connections running from the inside of the muscle cell, through the membrane, to the tissue outside. When a muscle contracts, mechanical force travels along this chain instead of pulling directly on the fragile cell membrane. Dystrophin essentially shields the membrane from being torn apart by the forces of normal movement.
What Happens When Dystrophin Is Absent
Without dystrophin, the muscle cell membrane has no structural reinforcement. Each contraction places stress directly on the membrane, causing small tears. Those tears allow calcium and other ions from outside the cell to flood in, disrupting the careful chemical balance the cell needs to survive. At the same time, essential molecules leak out.
A healthy cell can patch small membrane injuries. But in DMD, the damage is repetitive and cumulative. Muscles that work hardest, like those in the legs and pelvis, accumulate tears faster than the body can repair them. Over time, muscle fibers die and are replaced by scar tissue and fat, which cannot contract. This is why boys with DMD typically show their first motor difficulties around age 3 to 4: trouble running, frequent falls, difficulty climbing stairs, and a characteristic maneuver called Gowers’ sign, where a child uses their hands to “walk up” their own legs when rising from the floor. Enlarged calf muscles are another hallmark, caused by fat and scar tissue replacing lost muscle fiber.
The same process eventually affects the heart and the muscles used for breathing, which is why DMD shortens life expectancy even with modern care.
The Genetic Mutations Behind DMD
The gene that codes for dystrophin sits on the X chromosome, which is why DMD overwhelmingly affects boys (roughly 1 in 3,600 male births). Girls carry two X chromosomes, so a working copy on one can compensate for a faulty copy on the other. Boys have only one X, so a single mutation is enough to knock out dystrophin production entirely.
The dystrophin gene is the largest known human gene, making it an unusually big target for errors. In a large analysis of over 1,100 confirmed mutations, about 43% were large deletions (whole chunks of the gene missing), 11% were duplications (sections copied an extra time), and 46% were smaller point mutations (single-letter errors in the genetic code). The type of mutation matters for treatment, because some newer therapies are designed to work around specific deletion patterns.
How DMD Is Detected
One of the earliest and most reliable clues is an extremely elevated level of creatine kinase (CK) in the blood. CK is an enzyme normally locked inside muscle cells. When those cells are damaged, CK spills into the bloodstream. In healthy children, CK levels typically fall between 35 and 174 units per liter. In boys with DMD, levels can range from roughly 2,600 to over 45,000 units per liter, often 10 to 100 times the normal value. This blood test is usually the first step, followed by genetic testing to confirm the specific mutation.
Treatments Targeting the Missing Protein
Because the root problem is a single missing protein, treatment strategies focus on restoring at least a partial version of dystrophin to muscle cells. Two main approaches have reached the market.
Exon-Skipping Therapies
The dystrophin gene’s instructions are divided into segments called exons. In many DMD patients, a deletion in one exon throws the entire reading frame out of alignment, so the cell cannot produce any functional protein. Exon-skipping drugs work by telling the cell’s machinery to skip over a neighboring exon during the reading process, restoring the reading frame. The result is a shorter but partially functional dystrophin, similar to the milder protein seen in Becker muscular dystrophy.
Four exon-skipping drugs have received FDA approval, targeting exons 45, 51, and 53, which cover the most common deletion patterns. The first, targeting exon 51, was approved in 2016. Not every patient is eligible: the specific drug must match the patient’s particular mutation.
Gene Therapy
A more ambitious approach delivers a miniaturized version of the dystrophin gene directly into muscle cells using a harmless virus as a carrier. The full dystrophin gene is too large to fit inside any available viral delivery vehicle, so researchers engineered a compact “micro-dystrophin” gene that encodes the most critical functional regions of the protein.
The FDA approved a gene therapy called Elevidys for individuals aged 4 and older with a confirmed DMD gene mutation. It received traditional approval for patients who can still walk and accelerated approval for those who have already lost the ability to walk. There is one notable exception: the therapy is not used in patients with deletions in exon 8 or exon 9 of the dystrophin gene. Safety data in children under 4 remains insufficient to support its use in that age group.
Why Partial Dystrophin Matters
A useful comparison exists within the same disease family. Becker muscular dystrophy is caused by mutations in the same gene, but instead of eliminating dystrophin entirely, the mutations produce a shorter or less abundant version of the protein. Becker patients progress much more slowly and often remain ambulatory well into adulthood. This natural example is the proof of concept behind every current DMD therapy: you don’t need a perfect dystrophin gene to make a meaningful clinical difference. Even restoring a fraction of normal dystrophin levels can slow the relentless cycle of membrane damage, calcium flooding, and muscle fiber death that drives the disease forward.